My ePortfolio Register   

UK approval for panobinostat as a possible treatment for multiple myeloma

NICE has recommended panobinostat (also known as Farydak and manufactured by Novartis) as a possible treatment for people with multiple myeloma if they have had at least two prior therapies (including bortezomib and an immunomodulatory agent). 

Panobinostat is recommended only if it is provided with the discount agreed in the patient access scheme.

The decision follows public consultation on a preliminary decision not to recommend panobinostat, with the manufacturer responding to the consultation by submitting a revised economic analysis which allowed the committee to recommend the drug.

Panobinostat is a new type of oral anti-cancer treatment that works by disrupting a key mechanism which causes normal cells to turn cancerous.

According to Cancer Research UK, in 2012 there were just over 4,000 new cases of multiple myeloma in England.

Source: NICE

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence